A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma

作者：Shan-Shan Jiang, Yan Tang, Yaojun Zhang, De-Sheng Weng, Zhong-Guo Zhou, Ke Pan, Qiu-Zhong Pan, Qi-Jing Wang, Qing Liu, Jia He, Jing-Jing Zhao, Jiang Li, Min-Shan Chen, Alfred E. Chang, Qiao Li, Jian‐Chuan Xia · 发表于：Oncotarget · 年份：2015 · DOI：10.18632/oncotarget.5463 · 被引用次数：111 · 研究领域：CAR-T cell therapy research、Immune Cell Function and Interaction、Immunotherapy and Immune Responses

// Shan-Shan Jiang 1, * , Yan Tang 1, * , Yao-Jun Zhang 2, * , De-Sheng Weng 1 , Zhong-Guo Zhou 2 , Ke Pan 1 , Qiu-Zhong Pan 1 , Qi-Jing Wang 1 , Qing Liu 1 , Jia He 1 , Jing-Jing Zhao 1 , Jiang Li 1 , Min-Shan Chen 2 , Alfred E. Chang 3 , Qiao Li 3 , Jian-Chuan Xia 1 1 Department of Biotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 2 Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China 3 University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA * These authors have contributed equally to this work Correspondence to: Jian-Chuan Xia, e-mail: xiajch@mail.sysu.edu.cn Qiao Li, e-mail: qiaoli@umich.edu Keywords: primary hepatocellular carcinoma, autologous tumor-infiltrating lymphocytes, adoptive cell therapy Received: July 15, 2015      Accepted: September 01, 2015      Published: October 20, 2015 ABSTRACT This report describes an ongoing Phase I clinical trial testing the safety of adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) in patients with primary hepatocellular carcinoma (HCC). Fifteen HCC patients were treated with their activated and expanded TILs following tumor resection. From a total of 17 patients with HCC, TIL were successfully expanded from 15 patients (88%), whereas two patients showed minimal or no expans...